



Crescendo Biologics' CEO, Peter Pack to attend Jefferies Healthcare conference 15-16 November 2017

Cambridge, UK, 10 November 2017 – Crescendo Biologics Limited (Crescendo), the drug developer of Humabody® therapeutics, announces that its CEO, Peter Pack and CFO, Theo Harold will be attending the Jefferies Healthcare conference in London on 15-16 November 2017.

To arrange a meeting with the Company, please contact info@crescendobiologics.com.

Ends

For more information, please contact:

Crescendo Biologics Dr Peter Pack, CEO	Tel:44 (0)1223 497140 info@crescendobiologics.com
Instinctif Partners Dr Christelle Kerouedan / Melanie Toyne-Sewell	Tel:44 (0)20 7457 2020 crescendo@instinctif.com

Notes to Editors:

About Crescendo Biologics Ltd

Crescendo Biologics is a biopharmaceutical company discovering and developing potent, highly differentiated mono- and multi-specific Humabody® therapeutics in oncology. The Company's Humabody® therapeutics are based on its unique, patent protected, transgenic mouse platform generating 100% human V_H domain building blocks (Humabody® V_H) with superior biophysical properties.

Crescendo is pursuing novel Humabody®-based product opportunities, through in-house development and strategic partnerships in both multi-specific immuno-oncology modulators and HDCs (Humabody® Drug Conjugates), the next generation of ADCs.

Crescendo is located in Cambridge, UK, and is backed by blue-chip investors including Sofinnova Partners, Touchstone Innovations (formerly known as Imperial Innovations) and Takeda.

For more information, please visit the website: www.crescendobiologics.com.